Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Cash & Equivalents (2016 - 2025)

Adma Biologics (ADMA) has disclosed Cash & Equivalents for 14 consecutive years, with $87.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 15.04% year-over-year to $87.6 million, compared with a TTM value of $87.6 million through Dec 2025, down 15.04%, and an annual FY2025 reading of $87.6 million, down 15.04% over the prior year.
  • Cash & Equivalents was $87.6 million for Q4 2025 at Adma Biologics, up from $61.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $103.1 million in Q4 2024 and bottomed at $34.4 million in Q3 2021.
  • Average Cash & Equivalents over 5 years is $66.2 million, with a median of $65.9 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents tumbled 42.35% in 2021, then surged 112.61% in 2023.
  • Year by year, Cash & Equivalents stood at $51.1 million in 2021, then soared by 69.36% to $86.5 million in 2022, then tumbled by 40.65% to $51.4 million in 2023, then skyrocketed by 100.86% to $103.1 million in 2024, then dropped by 15.04% to $87.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for ADMA at $87.6 million in Q4 2025, $61.4 million in Q3 2025, and $90.3 million in Q2 2025.